Experimental Dermatology · 2013 · 38 citations · 12 references
MedicineMolecular BiologyOncologyGene ExpressionMetastasisMolecular OncologyCancer Cell SignalingOncogene ActivationOncogene MutationsOncogenic Signaling PathwaysProto-oncogene ActivationSignal Transduction In CancerApoptotic Resistance MechanismsBraf V600 MutationsBraf V600e MutationExtrinsic Apoptotic Pathway ResistanceMelanocytic Tumor Molecular PathologyMelanoma ProgressionOncogenic Braf SignalingOncogenic Splicing
The Bcl-2 family member Mcl-1 is essential for melanoma survival; however, the influence of oncogenic BRAF signalling remains elusive. In this study, Mcl-1 splice variant expression was determined in a panel of melanoma cell lines in relation to BRAF mutational status. Mcl-1L mRNA expression was increased in melanoma cells compared with primary melanocytes with significantly increased mRNA and protein expression observed in BRAF(V600E) mutant melanoma cells. Although no change in Mcl-1S mRNA was observed, Mcl-1S protein expression also increased in BRAF mutant melanoma cells. Additionally, while over-expression of mutant BRAF(V600E) increased both Mcl-1L and Mcl-1S expression, inhibition of hyperactive BRAF signalling resulted in decreased Mcl-1L expression. These studies suggest that the regulation of Mcl-1 expression by BRAF signalling is increased by oncogenic activation of BRAF, revealing a mechanism of apoptotic resistance which may be overcome by the use of more specifically targeted Mcl-1 inhibitors.
12
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty, Igor Puzanov, Kevin B. Kim et al. · New England Journal of Medicine · 2010 · 3.5K citations
Medicine, Oncology, Pharmacology +17
Jeehyeon Bae, Chandra P. Leo, Sheau Yu Hsu et al. · Journal of Biological Chemistry · 2000 · 277 citations · Full text